Skip to Main content Skip to Navigation
Master Thesis

Effet du Valsartan sur 3 marqueurs inflammatoires chez le sujet SAOS : comparaison à la CPAP

Abstract : This ancillary study, based on a cohort of 28 OSA patients, found no effect of Valsartan or CPAP on three inflammatory markers (CRPus, 11-TXB2, LTE4). The failure of CPAP to reduce these inflammatory biomarkers could be due to our population composition that mainly included overweight individuals, in whom obesity is a well known confounding factor associated to underlying inflammation. Valsartan is indicated in the treatment of essential hypertension. The decrease of cardiovascular risk which can be attributed to this molecule could be mainly due to its anti-hypertensive properties, and seems to be independent of potential anti-inflammatory effects. This lack of effect may be explained by the absence of PPAR-γ agonist property. A comparison between Valsartan and ARBs sharing this property, such as Irbesartan, on two matched groups could elucidate the underlying mechanism.
Document type :
Master Thesis
Complete list of metadata

Cited literature [26 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-00862341
Contributor : Jean-Hugues Morneau <>
Submitted on : Monday, September 16, 2013 - 2:43:08 PM
Last modification on : Tuesday, May 11, 2021 - 11:36:17 AM
Long-term archiving on: : Thursday, April 6, 2017 - 8:54:52 PM

Identifiers

  • HAL Id : dumas-00862341, version 1

Citation

Alexandre Behouche. Effet du Valsartan sur 3 marqueurs inflammatoires chez le sujet SAOS : comparaison à la CPAP. Sciences pharmaceutiques. 2013. ⟨dumas-00862341⟩

Share

Metrics

Record views

178

Files downloads

749